APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.
about
Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy.Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.The oncologic burden of hepatitis C virus infection: A clinical perspective.Epidemiologic features of 348 children with hepatitis C virus infection over a 30-year period: a nationwide survey in Japan.Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis.Monitoring the treatment of hepatitis C with directly acting antivirals by serological and molecular methods.Global elimination of hepatitis C virus infection: Progresses and the remaining challenges.Genetic variations in NF-κB were associated with the susceptibility to hepatitis C virus infection among Chinese high-risk population.Influence of IL28B and MxA gene polymorphisms on HCV clearance in Han Chinese population.Risk Assessment of Hepatocellular Carcinoma in Patients with Hepatitis C in China and the USA.Hepatitis C in Pregnancy.Comparative Antiviral Efficacy of Generic Sofosbuvir versus Brand Name Sofosbuvir with Ribavirin for the Treatment of Hepatitis C2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
P2860
Q36258800-42804E42-EA98-45E2-AD63-AE9FD07F1ADBQ37578288-AA9A0E65-43E4-4A71-A991-862AEC52CFDCQ39032538-DB7EE8CE-FC1E-4428-9966-9A32D1448C6FQ39104215-1E7E76BC-AF58-455D-8CA1-B911467E9031Q39418450-572BB4D1-2EED-4F28-A81F-C4E7C5DF435CQ40178123-46431C4C-8FFD-45C6-85F7-1845E7D99E75Q47128327-8D435C55-F02B-480E-A4A2-1E294D98BD07Q47132671-10DC1917-DD4C-4AB7-92FD-0A46ED550FFAQ47274792-C51B1E22-9A7A-4C3C-ABE0-CBF39BF48AB6Q47557031-6135E454-C8AC-4040-931A-7247A2533F3AQ47561355-F1289AA1-235B-48B1-802C-BFA0E74C9062Q47631237-7294B2CC-E1D3-416C-A4EF-B54E5005D09EQ54226744-7B5A1C75-AD04-4017-8440-A3EDEAAC0E5DQ58593930-3D5E3F23-D157-465D-BB03-AC2D636A5AD8Q58788714-7F78F9D6-AB55-4D42-9EA4-E0E00699991D
P2860
APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.
description
2016 nî lūn-bûn
@nan
2016 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
APASL consensus statements and ...... ology, and laboratory testing.
@ast
APASL consensus statements and ...... ology, and laboratory testing.
@en
type
label
APASL consensus statements and ...... ology, and laboratory testing.
@ast
APASL consensus statements and ...... ology, and laboratory testing.
@en
prefLabel
APASL consensus statements and ...... ology, and laboratory testing.
@ast
APASL consensus statements and ...... ology, and laboratory testing.
@en
P2093
P2860
P1476
APASL consensus statements and ...... iology, and laboratory testing
@en
P2093
A Kadir Dokmeci
Alaaeldin Ibrahim
Ankur Jindal
Barjesh Chander Sharma
Cosmas Rinaldi Adithya Lesmana
Darrell H G Crawford
Geofferey W McCaughan
George K K Lau
Jafri Wasim
Jose Sollano
P2860
P2888
P304
P356
10.1007/S12072-016-9736-3
P5008
P577
2016-05-26T00:00:00Z
P6179
1010129254